FDA Approves Rasonque for Pancreatic Cancer: When It’s Available and Cost

The FDA has approved Rasonque, a first-of-its-kind oral treatment for advanced pancreatic cancer, which significantly extends survival in late-stage clinical trials. The once-daily pill, developed by Revolution Medicines and known generically as daraxonrasib, blocks active forms of RAS, a family of proteins that drives tumor growth in most pancreatic adenocarcinoma cases.

With more than 90 percent of pancreatic cancers carrying cancer-driving mutations in KRAS, a member of the RAS gene family, Rasonque is the first medicine designed to broadly target the RAS pathway in pancreatic cancer. The drug is now available by prescription in the United States and is approved for adults with metastatic pancreatic cancer whose disease has progressed after prior treatment or who are not candidates for standard combination chemotherapy.

Rasonque's wholesale acquisition cost is $39,800 for a 30-day supply, and out-of-pocket costs will vary depending on insurance coverage and eligibility for financial assistance.

Brief written by urgent.news from Newsweek's own syndicated text. Machine-written — may contain errors; check the original before relying on it.